螺内酯治疗慢性充血性心力衰竭的疗效及其对血浆B型脑钠肽的影响

Efficacy of Spironolactone in the Treatment of Chronic Congestive Heart Failure and Its Effect on Plasma B-Type Brain Natriuretic Peptide

目的探讨分析螺内酯治疗慢性充血性心力衰竭的疗效及其对血浆B型脑钠肽的影响。方法方便选取该院2016年1月—2017年1月收治的98例慢性充血性心力衰竭患者,随机分为对照组和研究组,各49例,给予对照组患者传统治疗方法,给予研究组患者螺内酯治疗干预。对比分析两组患者BNP,EF%值和步行试验等,还需要对患者心功能分级进行评估。结果在对两组患者采取不同治疗方法之后,对照组患者BNP改善评分为(471.15±215.23)分,研究组患者BNP改善评分为(259.10±85.23)分,结果显示,对照组患者BNP改善程度显著低于研究组患者(t=6.241 3,P<0.05);对比分析两组患者EF%值,对照组患者EF%值为(34.11±1.14)%,研究组患者EF%值为(34.41±1.12)%,结果显示两组患者EF%值对比差异无统计学意义(t=1.345 7,P>0.05);两组患者在进行治疗之后,其心功能都得到不同程度的改善,对照组患者的治疗总有效率为75.51%,研究患者的治疗总有效率为93.88%,结果显示,对照组患者的治疗总有效率显著低于研究组患者,差异有统计学意义(χ~2=9.845,P<0.05)。结论针对慢性充血性心力衰竭患者给予基础治疗联合螺内酯治疗干预,可以降低患者血浆BNP值,缓解各项临床症状,在治疗期间患者不会出现高血钾血症,具有较高的安全性。

Objective To investigate the efficacy of spironolactone in the treatment of chronic congestive heart failure and its effect on plasma B-type brain natriuretic peptide. Methods Ninety-eight patients with chronic congestive heart failure admitted to the hospital from January 2016 to January 2017 were convenient selected and randomly divided into the control group and the study group ,each with 49 case. The traditional treatment methods were given to the control group, and the patients in the study group were given spironolactone treatment intervention. Comparative analysis of BNP, EF% and walk- ing tests in the two groups also required evaluation of the patient＇s cardiac function grading. Results After different treat- ments were used in the two groups, the BNP improvement score of the control group was （471.15＋215.23）points, and the BNP improvement score of the study group was （259.10＋85.23）points. The results showed that the BNP improvement in the control group was significant. The patients in the study group were lower than the study group （t=6.241 3, P〈0.05）. The EF% values of the two groups were compared. The EF% of the control group was （34.11＋1.14）%, and the EF% of the study group was （34.41±1.12）%, the results showed that the difference in EF% between the two groups was not statistically signifi- cant （t=1.345 7, P〉0.05）; the heart function of the two groups was improved after treatment, and the total effective rate of treatment in the control group for 75.51%, the total effective rate of the study patients was 93.88%. The results showed that the total effective rate of the control group was significantly lower than that of the study group, the difference was statistically significant （χ^2=9.845, P〈0.05）. Conclusion The combination of basal treatment and spironolactone in patients with chronic congestive heart failure can reduce the plasma BNP value and alleviate various clinical symptoms. During the treatment period, patients will not have hyperkalemia, with high safety.